TNF and Alzheimer disease: The results of this open label study supported the previously reported favorable safety profile of D ​+ ​Q in an AD relevant population, while additionally demonstrating a significant inverse relationship between reduced TNF-α levels with higher MoCA scores after D ​+ ​Q treatment, providing evidence for potential functional benefits of senolytic therapy in an AD relevant population, which will need to be further evaluated in larger, placebo-controlled cohorts.